Filter by audience:
Oral sessions summaries
Rimegepant 75 mg Provides Early and Sustained Relief of Migraine with a Single Oral Dose: Results from 3 Phase 3 Clinical Trials
Expert commentary by Stephanie J. Nahas, MD, MSEd, FAHS, FAAN
AHSAM 2020 - Oral session
Published on September 11, 2020
Wolff Award: Cognitive Networks Disarrangement in Patients with Migraine Predicts Cutaneous Allodynia
AHSAM 2020 - Oral session
Published on July 17, 2020
Early Career Award: Alterations in Functional Connectivity during Different Phases of the Triggered Migraine Attack
AHSAM 2020 - Oral session
Published on July 17, 2020
Solomon Award Lecture: Observations 2020 - 'Teaching Headache'
AHSAM 2020 - Oral session
Published on July 17, 2020
Graham Award: Practical Approach to Eye Pain and Photophobia
AHSAM 2020 - Oral session
Published on July 17, 2020
Headache & COVID-19: A Short-term Challenge with Long-term Insights
AHSAM 2020 - Oral session
Published on July 17, 2020
COVID-19 and Headache: The New York Experience
AHSAM 2020 - Oral session
Published on July 17, 2020
Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers
AHSAM 2020 - Oral session
Published on July 17, 2020
A Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update – 29 Years of Safety Observation
Expert commentary by Carrie Dougherty, MD, FAHS
AHSAM 2020 - Oral session
Published on July 30, 2020
Retrospective Review of the Use of Anti-CGRP Monoclonal Antibodies to Treat Headaches in Patients with Idiopathic Intracranial Hypertension
Expert commentary by Deborah I. Friedman, MD, MPH, FAAN, FAHS
AHSAM 2020 - Oral session
Published on July 30, 2020
The Role of Cerebellar CGRP in Migraine-like Behavior
Expert commentary by Amynah Pradhan, PhD
AHSAM 2020 - Oral session
Published on July 23, 2020
Characteristics of Individuals with Migraine Who Are Eligible for Novel CGRP Monoclonal Antibodies: Results of the OVERCOME Study
Expert commentary by Carrie Dougherty, MD, FAHS
AHSAM 2020 - Oral session
Published on July 30, 2020
Multiple, Once-daily, Oral Doses of 170 Mg Atogepant for 28 Days Are Safe and Well Tolerated with No Clinically Significant Effect on Alanine Aminotransferase in Healthy Adults
Expert commentary by Jessica Ailani, MD
AHSAM 2020 - Oral session
Published on September 3, 2020
Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2
Expert commentary by Jessica Ailani, MD
AHSAM 2020 - Oral session
Published on September 3, 2020
Improved Functionality, Satisfaction, and Global Impression of Change with Ubrogepant for the Acute Treatment of Migraine in Triptan Insufficient Responders
Expert commentary by Randolph W. Evans, MD
AHSAM 2020 - Oral session
Published on September 11, 2020
Efficacy and Safety of AXS-07 (MoSEIC™ Meloxicam/Rizatriptan) in the Acute Treatment of Migraine: Results from the MOMENTUM Phase 3 Trial
Expert commentary by Randolph W. Evans, MD
AHSAM 2020 - Oral session
Published on September 11, 2020
A Real-World Comparison of Erenumab and Galcanezumab in a Tertiary Headache Center
Expert commentary by Jessica Ailani, MD
AHSAM 2020 - Oral session
Published on September 17, 2020 | NEW
Improving Headache Management in the Pediatric Emergency Department
AHSAM 2020 - Oral session
Published on July 30, 2020
Childhood and Adolescent Migraine Prevention [CHAMP] Trial: The 3-year Follow-up Survey Results
Expert commentary by Marcy Yonker, MD, FAHS
AHSAM 2020 - Oral session
Published on July 30, 2020
Exploring Naturally Occurring Clinical Subgroups of Post-traumatic Headache
Expert commentary by Nada Hindiyeh, MD
AHSAM 2020 - Oral session
Published on July 23, 2020
Effects of Pre-injury Migraine Frequency on Post-traumatic Headache Recovery in the General Adult Population: The Toronto Concussion Study
Expert commentary by Nada Hindiyeh, MD
AHSAM 2020 - Oral session
Published on July 23, 2020
Mild TBI induces long-lasting sensitization to pain in mice
Expert commentary by Andrew Russo, PhD
AHSAM 2020 - Oral session
Published on August 27, 2020
